Abstract
Ravulizumab (ravulizumab-cwvz; ULTOMIRIS), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
